Antifibrotic potential of a selective COX-2 inhibitor (celecoxib) on liver fibrosis in rats

Comparative Clinical Pathology

Volumn 22, Issue 3, 2013, Pages 425-430

  Ftahy, Mona M ^a   Latif, Noha S Abdl ^b   Alalkamy, Essam F ^b   El Batrawi, Fatma A ^b   Galal, Ahmad H ^b   Khatab, Hany M ^b  

^a Cairo University   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Celecoxib; COX 2 inhibitors; Rat liver fibrosis

Indexed keywords

EID: 84877624644     PISSN: 16185641     EISSN: 1618565X     Source Type: Journal    
DOI: 10.1007/s00580-012-1427-4     Document Type: Article

References (32)

1. Albanis EL, Safadi RL, Friedman SL (2003) Treatment of hepatic fibrosis: almost there. Curr Gastroenterol Rep 5: 48-56.
2. Aydin AF, Kusku-Kiraz Z, Dogru-Abbasoglu S, Gulluoglu M, Uysal M, Kocak-Toker N (2010) Effect of carnosine against thioacetamide-induced liver cirrhosis in rat. Peptides 31: 67-71.
3. Bataller R, Brenner D (2005) Liver fibrosis. J Clin Invest 115(2): 209-218.
4. Bedossa P, Poynard T (1998) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperate Study Group. Hepatology 24: 289-293.
5. Chávez E, Segovia J, Shibayama M, Tsutsumi V, Vergara P, Castro-Sánchez L, Salazar EP, Moreno MG, Muriel P (2010) Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat. Liver Int 30(7): 969-978.
6. Cheng J, Imanishi H, Liu W et al (2002) Inhibition of the expression of alpha-smooth muscle actin in human hepatic stellate cell line, LI90, by a selective cyclooxygenase 2 inhibitor, NS-398. Biochem Biophys Res Commun 297: 1128-1134.
7. Efsen E, Bonacchi A, Pastacaldi S et al (2001) Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. Hepatology 33: 713-721.
8. Friedman SL (2004) Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications. Nat Clin Pract Gastroenterol Hepatol 1: 98-105.
9. Guerra RR, Trotta MR, Parra OM, Avanzo JL, Bateman A (2009) Modulation of extracellular matrix by nutritional hepatotrophic factors in thioacetamide-induced liver cirrhosis in the rat. Braz J Med Biol Res 42: 1027-1034.
10. Hu KQ (2003) Cyclooxygenase 2 (COX-2) prostanoid pathway and liver diseases. Prostaglandins Leukot Essent Fatty Acids 69: 329-337.
11. Huang HC, Wang SS, Chan CY, Chen YC, Lee FY, Chang FY (2007) Role of hepatic nitric oxide synthases in rats with thioacetamide induced acute liver failure and encephalopathy. J Chin Med Assoc 760: 16-23.
12. Hui AY, Dannenberg AJ, Sung JJ et al (2004) Prostaglandin E2 inhibits transforming growth factor beta 1-mediated induction of collagen alpha 1(I) in hepatic stellate cells. J Hepatol 41: 251-258.
13. Hui AY, Leung WK, Chan HL et al (2006) Effect of celecoxib on experimental liver fibrosis in rat. Liver Int 26: 125-136.
14. Hung KS, Lee TH, Chou WY, Wu CL, Cho CL, Lu CN (2005) Interleukin-10 gene therapy reverses thioacetamide-induced liver fibrosis in mice. Biochem Biophys Res Commun 336: 324-331.
15. Ishak KG, Baptista A, Bianchi L (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
16. Ismail M, Pinzani M (2009) Reversal of liver fibrosis. Saudi J Gastroenterol 15(1): 72-79.
17. Jeong DH, Lee GP, Jeong WI, Do SH, Yang HJ, Yuan DW, Park HY, Kim KJ, Jeong KS (2005) Alterations of mast cells and TGF-β1 on the silymarin treatment for CCl4-induced hepatic fibrosis. World J Gastroenterol 11(8): 1141-1148.
18. Jidong C, Toshikazu H (2005) The significance of COX-2 and COX-2 inhibitors in liver fibrosis and liver cancer. Current Medicinal Chemistry-Anti-Inflammatory & Anti-Allergy Agents 4(2): 199-206.
19. Kawamori T, Rao CV, Seibert K et al (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58: 409-412.
20. Kusunoki N, Yamazaki R, Kawai S (2002) Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors. Arthritis Rheum 46: 3159-3167.
21. Lee HS, Huang GT, Chen CH, Chiou LL, Lee CC, Yang PM, Chen DS, Sheu JC (2001) Less reversal of liver fibrosis after prolonged carbon tetrachloride injection. Hepatogastroenterology 48: 1312-1315.
22. Leng J, Han C, Demetris AJ et al (2003) Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib induced apoptosis. Hepatology 38: 756-768.
23. Manea F, Radovan C, Schoonman J (2006) Amperometric determination of thiourea in alkaline media on a copper oxide-copper electrode. J Applied Electrochem 36: 1075-1081.
24. Miyazawa K, Moriyama M, Mikuni M, Matsumura H, Aoki H, Shimizu T, Yamagami H, Kaneko M, Shioda A, Tanaka N, Arakawa Y (2003) Analysis of background factors and evaluation of a population at high risk of hepatocellular carcinoma. Intervirology 46: 150-156.
25. Mohammed NA, El-Aleem SA, El-Hafiz HA, McMahon RF (2004) Distribution of constitutive (COX-1) and inducible (COX2) cyclooxygenase in postviral human liver cirrhosis. Pathol 57: 350-354.
26. Ohayon O, Mawasi N, Pevzner A, Tryvitz A, Gildor T, Pines M, Rojkind M, Paizi M, Spira G (2008) Halofuginone upregulates the expression of heparanase in thioacetamide-induced liver fibrosis in rats. Lab Invest 88: 627-633.
27. Paik Y-H, Kim JK, Lee JI, Kang SH, Kim DY, An SH, Lee SJ, Lee DK, Han K-H, Chon CY, Lee SI, Lee KS, Brenner DA (2009) Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut 58: 1517-1527.
28. Sung YK, Hwang SY, Kim JO, Bae HI, Kim JC, Kim MK (2004) The correlation between cyclooxygenase-2 expression and hepatocellular carcinogenesis. Mol Cells 17: 35-38.
29. Wang CH, Jawan B, Lee TH, Hung KS, Chou WY, Lu CN (2004) Single injection of naked plasmid encoding α-melanocyte-stimulating hormone protects against thioacetamide-induced acute liver failure in mice. Biochem Biophys Res Commun 322: 153-161.
30. Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM (2007) Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology 46(1): 135-140.
31. Yu J, Wu CW, Chu ES (2008) Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice. Biochem Biophys Res Commun 372: 571-577.
32. Zois CD, Baltayiannis GH, Karayiannis P, Tsianos EV (2008) Systematic review: hepatic fibrosis-regression with therapy. Aliment Pharmacol Ther 28(10): 1175-1187.